Analysis: Vaccine firms may benefit from incentive under Obama

01/13/2009 |

The incoming Obama administration may not prioritize financing research programs and broadening production capacity for vaccines as it pushes for new goals and spending targets for health care, according to this RPM Report analysis. However, drugmakers may benefit from "enhanced government-stimulated markets for vaccine products" as health leaders draw up plans for immunization programs aimed at adolescents and the elderly, the article says.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC